The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction

The high activity of Histone deacetylases (HDACs) in hepatocellular carcinoma (HCC) usually positively correlates with poor prognosis of patients. Accordingly histone deacetylases inhibitors (HDACis) are considered to be potential agents treating patients with HCC. In our study, we evaluated effect...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Biol Sci
Main Authors: He, Bin, Dai, Longfei, Zhang, Xiaoqian, Chen, Diyu, Wu, Jingbang, Feng, Xiaode, Zhang, Yanpeng, Xie, Haiyang, Zhou, Lin, Wu, Jian, Zheng, Shusen
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6231215/
https://ncbi.nlm.nih.gov/pubmed/30443188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijbs.27661
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados